StockData

ProQR Therapeutics vs Stoke Therapeutics

PRQR and STOK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PRQR and STOK compare

ProQR Therapeutics grew revenue faster over the last twelve months (11.4% versus −86.2% for Stoke Therapeutics).

ProQR Therapeutics keeps more of each dollar of sales as profit, with a net margin of −229% compared with −754% at Stoke Therapeutics.

ProQR Therapeutics scores higher on the StockData Score (7 against 6 for Stoke Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPRQRSTOK
Size and price
Market cap–$1.7B
Share price$1.15$26.41
Change, 1 year−47.0%−0.38%
Change, 5 years−84.0%5.2%
Beta (5Y)2.580.98
Employees59170
StockData Score
Total score7 (better)6
Valuation score00
Growth score2 (better)1
Performance score2 (better)0
Health score35 (better)
Dividend score00
Valuation
P/S–61.8×
P/B–4.9×
FCF yield–−10.6%
Fair value–$9.66
Margin of safety–−173%
Growth
Revenue growth (TTM)11.4% (better)−86.2%
Net income growth (TTM)–−496%
EPS growth (TTM)–−501%
Profitability
Operating margin−233% (better)−810%
Net margin−229% (better)−754%
FCF margin−273% (better)−655%
Return on equity−57.4% (better)−61.1%
Return on invested capital–−252%
Financial health
Debt / equity0.06 (better)0.00
Interest coverage–−4856.0×
Current ratio3.497.69 (better)
Altman Z-score–18.01
Piotroski F-score15 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions57.6%120%
Held by insiders37.8%41.6%
Insider net buying, 12 months$1.3M (better)−$6.7M
Short interest, % of float–28.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.